Zacks Investment Research has recently initiated coverage of Kewaunee Scientific Corporation (KEQU) with a "Neutral" recommendation, highlighting the company's strong order backlog and stable domestic performance while acknowledging ongoing challenges in its international operations and rising costs. Kewaunee Scientific boasts a solid order backlog, reaching $159.4 million as of July 31, 2024. This growth in the backlog reflects continued demand, providing strong visibility into future revenues. The company ...